Drugmakers slash prices to be eligible for China's bulk-buy program

Topics Drugmaker | Pharma sector | Pharma


Global pharmaceutical majors and generic drugmakers chopped by 53% on average prices of some of their off-patent products in the latest bidding round under China's national bulk-buy program, government officials said late on Friday.

Beijing has been pushing forward the program where drugmakers have to go through a bidding process and cut prices low enough to be considered over generic copies and be allowed to sell their products at public hospitals via large-volume government procurement. Some global firms such as AstraZeneca.....

This article is no longer available in our repository.

There could be multiple reasons for this.